FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter referred to as FRONTEO) announced that the 6th Annual Meeting of the Japanese Society of Toxicology (Annual Chairman: Satoshi Kitajima / Department of Toxicology, Biosafety Research Center, National Institute of Health Sciences), orally and I would like to inform you that I gave a poster presentation.

　FRONTEO utilizes in-house developed natural language processing AI to build unique technologies and techniques for comprehensive and objective analysis of vast amounts of text information and arithmetic between words.This presentation is an example of utilizing the strengths of this technology, which finds notable factors from among a huge number of factors, for drug safety evaluation. The onset of DILI is affected by many factors, making it extremely difficult to predict.In this study, we focused on the relationship between DILI and genes, and examined the applicability of natural language processing AI to search for DILI influence factors from the viewpoint of hypothesis generation.

　First, we constructed a DILI discriminant model using AI.Next, in order to find candidate factors that reduce DILI risk, we applied an approach that takes advantage of the features of natural language AI.As a result, 24 genes classified into 30 functions were extracted, including several genes that have not been reported to be related to DILI.Based on the above, this approach was considered to be effective in generating hypotheses to explore factors that affect DILI risk.

　This time, we focused on DILI as part of the verification, but by changing the discriminant model used, we can generate important hypotheses from searching for other organ toxicity onset risk factors to searching for highly novel therapeutic targets in drug discovery. It is considered a widely applicable approach.

　FRONTEO will contribute to improving the quality of medical care through research, development and provision of AI technology and analysis methods that contribute to the efficiency and progress of drug discovery research.

　The impact of this matter alone on the Company's business performance will be minor.

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO is a data analysis company that provides various AI solutions and services using the in-house developed AI engine "KIBIT". Based on the philosophy of "providing solutions that do not overlook risks and opportunities buried in records and realizing fairness in the information society," extract meaningful and important information from vast amounts of text data and complex networks. Our strengths are natural language processing and network analysis technologies that support advanced judgments by experts.We are developing businesses in the areas of legal tech AI, business intelligence, life science AI, and economic security, and contributing to solving various corporate and social issues. Founded in August 2003, listed on Tokyo Stock Exchange Mothers (currently Tokyo Stock Exchange Growth) on June 8, 2007.The company operates in Japan, the United States, South Korea, and Taiwan.Acquisition of first-class medical device manufacturing and sales business license, notification of controlled medical device sales business.Capital 6 yen (as of March 26, 3,042,317).

* FRONTEO and KIBIT are registered trademarks of FRONTEO in Japan.